Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases

Nature Communications

Volumn 7, Issue , 2016, Pages

  Cannavo, Alessandro ^a   Liccardo, Daniela ^a   Eguchi, Akito ^a   Elliott, Katherine J ^a   Traynham, Christopher J ^a   Ibetti, Jessica ^a   Eguchi, Satoru ^a   Leosco, Dario ^b   Ferrara, Nicola ^b,c   Rengo, Giuseppe ^b,c   Koch, Walter J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 5; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR KINASE; RETINA S ANTIGEN;

CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; HORMONE; PATHOLOGY; PROTEIN; RODENT; TOXICITY;

ADULT; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL FRACTIONATION; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; PATHOLOGY; PROTEIN TARGETING; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; CELL CULTURE TECHNIQUE; CELL MOTION; CHEMICALLY INDUCED; GENE EXPRESSION REGULATION; GENETICS; HEART DISEASE; HEART FAILURE; METABOLISM; MUSCLE CELL; PHYSIOLOGY; SIGNAL TRANSDUCTION;

MUS;

ALDOSTERONE; ANIMALS; ARRESTINS; BETA-ARRESTINS; CELL CULTURE TECHNIQUES; CELL MOVEMENT; G-PROTEIN-COUPLED RECEPTOR KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART DISEASES; HEART FAILURE; HUMANS; MICE; MICROSCOPY, CONFOCAL; MUSCLE CELLS; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION;

EID: 84960172266     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10877     Document Type: Article

References (61)

1. Briet, M., Schiffrin, E. L. Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 6, 261-273 (2010).
2. Swedberg, K., Eneroth, P., Kjekshus, J., Wilhelmsen, L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82, 1730-1736 (1990).
3. Jorde, U. P. et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106, 1055-1057 (2002).
4. Gutierrez-Marcos, F. M. et al. Atrial natriuretic peptide in patients with acute myocardial infarction without functional heart failure. Eur. Heart J. 12, 503-507 (1991).
5. Yoshida, M. et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest. Heart Fail. 11, 12-16 (2005).
6. Marney, A. M., Brown, N. J. Aldosterone and end organ damage. Clin. Sci. 113, 267-278 (2007).
7. Brilla, C. G., Weber, K. T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893-901 (1992).
8. Takeda, Y., Yoneda, T., Demura, M., Usukura, M., Mabuchi, H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 105, 677-679 (2002).
9. Yoshida, K. et al. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens. Res. 28, 447-455 (2005).
10. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999).
11. Pitt, B. et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
12. Martinez, D. V. et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 39, 614-618 (2002).
13. He, B. J. et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med. 17, 1610-1618 (2011).
14. Hayashi, H. et al. Aldosterone nongenomically produces NADPH oxidasedependent reactive oxygen species and induces myocyte apoptosis. Hypertens. Res. 31, 363-375 (2008).
15. de Almeida, P. W. et al. Functional cross-talk between aldosterone and angiotensin-(1-7) in ventricular myocytes. Hypertension 61, 425-430 (2013).
16. Lemarié, C. A. et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ. Res. 105, 852-859 (2009).
17. Di Zhang, A. et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52, 1060-1067 (2008).
18. Tsai, C. F., Yang, S. F., Chu, H. J., Ueng, K. C. Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogenactivated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int. J. Cardiol. 169, 17-28 (2013).
19. Akazawa, H., Yabumoto, C., Yano, M., Kudo-Sakamoto, Y., Komuro, I. ARB and cardioprotection. Cardiovasc. Drugs Ther. 27, 155-160 (2013).
20. Cannavo, A., Liccardo, D., Koch, W. J. Targeting cardiac b-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front. Physiol. 4, 264 (2013).
21. Sato, P. Y., Chuprun, J. K., Schwartz, M., Koch, W. J. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiol. Rev. 95, 377-404 (2015).
22. Dzimiri, N., Muiya, P., Andres, E., Al-Halees, Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur. J. Pharmacol. 489, 167-177 (2004).
23. Iaccarino, G. et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur. Heart J. 26, 1752-1758 (2005).
24. Hata, J. A. et al. Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J. Card. Fail. 12, 360-368 (2006).
25. Rockman, H. A. et al. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc. Natl Acad. Sci. USA 93, 9954-9959 (1996).
26. Rajagopal, K. et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc. Natl Acad. Sci. USA 103, 16284-16289 (2006).
27. Gold, J. I. et al. Nuclear translocation of cardiac G protein-coupled receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process. PLoS ONE 8, e57324 (2013).
28. Ciccarelli, M. et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 123, 1953-1962 (2011).
29. Chen, M. et al. Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. Circ. Res. 112, 1121-1134 (2013).
30. Fan, Q. et al. Myocardial ablation of G protein-coupled receptor kinase 2 (GRK2) decreases ischemia/reperfusion injury through an anti-intrinsic apoptotic pathway. PLoS ONE 8, e66234 (2013).
31. Gold, J. I., Gao, E., Shang, X., Premont, R. T., Koch, W. J. Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ. Res. 111, 1048-1053 (2012).
32. Kim, J., Ahn, S., Rajagopal, K., Lefkowitz, R. J. Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J. Biol. Chem. 284, 11953-11962 (2009).
33. Claing, A., Laporte, S. A., Caron, M. G., Lefkowitz, R. J. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog. Neurobiol. 66, 61-79 (2002).
34. Callera, G. E. et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 46, 1032-1038 (2005).
35. Fessart, D., Simaan, M., Laporte, S. A. c-Src regulates clathrin adapter protein 2 interaction with beta-arrestin and the angiotensin II type 1 receptor during clathrin-mediated internalization. Mol. Endocrinol. 19, 491-503 (2005).
36. Koch, W. J. et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268, 1350-1353 (1995).
37. Callera, G. E. et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45, 773-779 (2005).
38. Kuroda, J. et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc. Natl Acad. Sci. USA 107, 15565-15570 (2010).
39. Ashton, A. W. et al. Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury. Mol. Endocrinol. 29, 1144-1155 (2015).
40. Xue, B. et al. Estrogen receptor-beta (ERb) in the PVN and RVLM plays an essential protective role in aldosterone/salt-induced hypertension in female rats. Hypertension 61, 1255-1262 (2013).
41. Hullmann, J. E. et al. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ. Res. 115, 976-985 (2014).
42. Colella, M., Pozzan, T. Cardiac cell hypertrophy in vitro: role of calcineurin/NFAT as Ca2\+ signal integrators. Ann. NY Acad. Sci. 1123, 64-68 (2008).
43. Weber, K. T. Aldosterone in congestive heart failure. N. Engl. J. Med. 345, 1689-1697 (2001).
44. Keidar, S. et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109, 2213-2220 (2004).
45. Raake, P. W. et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ. Res. 103, 413-422 (2008).
46. Messaoudi, S. et al. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension 61, 361-367 (2013).
47. Dzimiri, N. et al. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur. J. Pharmacol. 489, 167-177 (2004).
48. Rengo, G. et al. Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. Eur. J. Prev. Cardiol. 21, 4-11 (2014).
49. Tachibana, H., Naga Prasad, S. V., Lefkowitz, R. J., Koch, W. J., Rockman, H. A. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation 111, 591-597 (2005).
50. Raake, P. W. et al. AAV6.bARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur. Heart J. 34, 1437-1447 (2013).
51. Fejes-Tóth, G., Náray-Fejes-Tóth, A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling Endocrinology 148, 1502-1510 (2007).
52. Jaffe, I. Z., Mendelsohn, M. E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96, 643-650 (2005).
53. Miller, 3rd C. A., Tan, X., Wilson, M., Bhattacharyya, S., Ludwig, S. Single plasmids expressing human steroid hormone receptors and a reporter gene for use in yeast signaling assays. Plasmid 63, 73-78 (2010).
54. Lymperopoulos, A., Rengo, G., Zincarelli, C., Soltys, S., Koch, W. J. Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol. Ther. 16, 302-307 (2008).
55. Martini, J. S. et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc. Natl Acad. Sci. USA 105, 12457-12462 (2008).
56. Brand, M. D., Nicholls, D. G. Assessing mitochondrial dysfunction in cells. Biochem. J. 435, 297-312 (2011).
57. Cannavo, A. et al. Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation. Apoptosis 18, 1252-1261 (2013).
58. Perrino, C. et al. Genetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure. J. Am. Heart Assoc. 2, e000086 (2013).
59. Cannavo, A. et al. bARKct gene-therapy improves b2-adrenergic receptordependent neoangiogenesis following hindlimb ischemia. J. Pharmacol. Exp. Ther. 115, 228411 (2015).
60. Matkovich, S. J. et al. Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ. Res. 99, 996-1003 (2006).
61. Agah, R. et al. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J. Clin. Invest. 100, 169-179 (1997).